Novel Use of Glucagon-Like Peptide-1 (GLP-1) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists in Maturity-Onset Diabetes of the Young (MODY)

Nov 20, 2025Cureus

New use of GLP-1 and combined GIP/GLP-1 treatments in young-onset diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Six patients with genetically confirmed MODY showed improved HbA1c levels after treatment with incretin-based therapies.

HbA1c levels improved by 1.0-4.1 percentage points for all patients following treatment.
Body weight decreased by 2.6-29 kg in patients receiving incretin therapies.
Three out of four patients who were previously using insulin were able to discontinue its use.
Insulin-naïve patients maintained good blood sugar control without starting insulin.
These results indicate that incretin-based therapies could be a safe alternative for managing MODY in specific genotypes.

AI simplified

Introduction Maturity-onset diabetes of the young (MODY), particularly due to HNF1A variants, is usually treated with sulfonylureas or insulin. In patients with excess weight or poor glycaemic control, these approaches can be challenging. Incretin-based therapies may provide a safer and more effective alternative. Methods We conducted a retrospective case series at Tawam Hospital (2019-2024), including patients with genetically confirmed MODY who received a Glucagon-like peptide-1 (GLP-1) receptor agonist or dual GLP-1/Glucose-dependent insulinotropic polypeptide (GIP) receptor agonist for at least three months. Clinical data, including HbA1c, body mass index (BMI), and insulin use, were extracted from medical records. The primary outcome was change in HbA1c; secondary outcomes included changes in BMI and insulin requirements. Results Six patients were included (five with HNF1A variants, one with combined PAX4/PDX1 variants). At baseline, HbA1c ranged from 7.3% to 10.6% and BMI from 25.1 to 36.7 kg/m². Following treatment, HbA1c improved in all cases (reductions of 1.0-4.1 percentage points) and weight decreased by 2.6-29 kg. Three of four insulin-treated patients discontinued insulin, while insulin-naïve patients maintained good glycaemic control without insulin initiation. Conclusion GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists improved glycaemic control, reduced body weight, and decreased insulin dependency in MODY patients. These findings suggest incretin-based therapies may be a safe and effective option in selected genotypes, meriting further evaluation in prospective studies.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Novel Use of Glucagon-Like Peptide-1 (GLP-1) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists in Maturity-Onset Diabetes of the Young (MODY)

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief